RESUMO
BACKGROUND: There is strong evidence supporting the efficacy of exercise oncology programs to improve physical and psychosocial outcomes during active treatment. However, there is a paucity of evidence on the effect of exercise on healthcare utilization and cost analyzes of exercise oncology programs. AIMS: Our objective was to assess the effects of a pragmatic exercise oncology program (ENACT) during active chemotherapy treatment on healthcare utilization and associated costs. METHODS: We conducted post-hoc analyzes on 160 ENACT participants and 75 comparison participants matched on cancer site, stage, age range, and gender. We obtained complete healthcare utilization histories for each patient (specific to emergency department [ED] visits and hospital admissions) coinciding with their participation in ENACT. A sub-analysis was conducted for advanced stage breast, gastrointestinal, and pancreatic cancer patients. RESULTS: Healthcare costs for patients who participated in the ENACT exercise oncology intervention were numerically lower than healthcare costs for the comparison group, even after accounting for the cost of the intervention. However, the differences were not statistically significant. CONCLUSION: Our findings suggest that an exercise oncology program during active chemotherapy treatment are at least cost neutral for all cancer patients, including advanced stage cancers. Additional research is warranted to evaluate the potential for exercise oncology programs to reduce healthcare utilization, particularly in advanced cancer patients.
Assuntos
Exercício Físico , Neoplasias , Feminino , Custos de Cuidados de Saúde , Humanos , Masculino , Neoplasias/tratamento farmacológico , Neoplasias/terapia , Aceitação pelo Paciente de Cuidados de Saúde , Ensaios Clínicos Pragmáticos como AssuntoAssuntos
Sobreviventes de Câncer , Neoplasias , Humanos , Neoplasias/complicações , Neoplasias/terapia , SobrevivênciaRESUMO
BACKGROUND: Multiple international organizations have called for exercise to become standard practice in the setting of oncology care. The feasibility of integrating exercise within systemic chemotherapy has not been investigated. METHODS: Patients slated to receive infusion therapy between April 2017 and October 2018 were screened for possible inclusion. The study goal was to establish the acceptability and feasibility of embedding an exercise professional into the chemotherapy infusion suite as a method of making exercise a standard part of cancer care. The exercise prescriptions provided to patients were individualized according to results of brief baseline functional testing. RESULTS: In all, 544 patients were screened, and their respective treating oncologists deemed 83% of them to be medically eligible to participate. After further eligibility screening, 226 patients were approached. Nearly 71% of these patients (n = 160) accepted the invitation to participate in the Exercise in All Chemotherapy trial. Feasibility was established because 71%, 55%, 69%, and 63% of the aerobic, resistance, balance, and flexibility exercises prescribed to patients were completed. Qualitative data also supported the acceptability and feasibility of the intervention from the perspective of patients and clinicians. The per-patient cost of the intervention was $190.68 to $382.40. CONCLUSIONS: Embedding an exercise professional into the chemotherapy infusion suite is an acceptable and feasible approach to making exercise standard practice. Moreover, the cost of the intervention is lower than the cost of other common community programs. Future studies should test whether colocating an exercise professional with infusion therapy could reach more patients in comparison with not colocating. LAY SUMMARY: Few studies have tested the implementation of exercise for patients with cancer by embedding an exercise professional directly into the chemotherapy infusion suite. The Exercise in All Chemotherapy trial shows that this approach is both acceptable and feasible from the perspective of clinicians and patients.
Assuntos
Antineoplásicos/uso terapêutico , Exercício Físico , Neoplasias/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Custos e Análise de Custo , Estudos de Viabilidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico , Segurança do Paciente , Seleção de Pacientes , Desempenho Físico Funcional , Desenvolvimento de Programas/economiaRESUMO
PURPOSE: Breast cancer-related lymphedema is an adverse effect of breast cancer surgery affecting nearly 30% of US breast cancer survivors (BCS). Our previous analysis showed that, even 12 years after cancer treatment, out-of-pocket healthcare costs for BCS with lymphedema remained higher than for BCS without lymphedema; however, only half of the cost difference was lymphedema-related. This follow-up analysis examines what, above and beyond lymphedema, contributes to cost differences. METHODS: This mixed methods study included 129 BCS who completed 12 monthly cost diaries in 2015. Using Cohen's d and multivariable analysis, we compared self-reported costs across 13 cost categories by lymphedema status. We elicited quotes about specific cost categories from in-person interviews with 40 survey participants. RESULTS: Compared with BCS without lymphedema, BCS with lymphedema faced 122% higher mean overall monthly direct costs ($355 vs $160); had significantly higher co-pay, medication, and other out-of-pocket costs, lower lotion costs; and reported inadequate insurance coverage and higher costs that persisted over time. Lotion and medication expenditure differences were driven by BCS' socioeconomic differences in ability to pay. CONCLUSIONS: Elevated patient costs for BCS with lymphedema are for more than lymphedema itself, suggesting that financial coverage for lymphedema treatment alone may not eliminate cost disparities. IMPLICATIONS FOR CANCER SURVIVORS: The economic challenges examined in this paper have long been a concern of BCS and advocates, with only recent attention by policy makers, researchers, and providers. BCS identified potential policy and programmatic solutions, including expanding insurance coverage and financial assistance for BCS across socioeconomic levels.
Assuntos
Neoplasias da Mama/complicações , Neoplasias da Mama/economia , Sobreviventes de Câncer , Efeitos Psicossociais da Doença , Linfedema/economia , Linfedema/etiologia , Idoso , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/patologia , Sobreviventes de Câncer/estatística & dados numéricos , Feminino , Gastos em Saúde/estatística & dados numéricos , Humanos , Cobertura do Seguro/estatística & dados numéricos , Linfedema/epidemiologia , Pessoa de Meia-Idade , Inquéritos e Questionários , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: The goal of this study was to develop and assess intra- and interrater reliability and validity of a clinical evaluation tool for breast cancer-related lymphedema, for use in the context of outcome evaluation in clinical trials. DESIGN: Blinded repeated measures observational study. SETTING: Outpatient research laboratory. PARTICIPANTS: Breast cancer survivors with and without lymphedema (N=71). INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: The assessment of intraclass correlation coefficients (ICCs) for the Breast Cancer-Related Lymphedema of the Upper Extremity (CLUE) standardized clinical evaluation tool. RESULTS: Intrarater reliability for the CLUE tool was ICC: 0.88 (95% confidence interval [95% CI], 0.71-0.96). Interrater reliability for the CLUE tool was ICC: 0.90 (95% CI, 0.79-0.95). Concurrent validity of the CLUE score (Pearson r) was 0.79 with perometric interlimb difference and 0.53 with the Norman lymphedema overall score. CONCLUSIONS: The CLUE tool shows excellent inter- and intrarater reliability. The overall CLUE score for the upper extremity also shows moderately strong concurrent validity with objective and subjective measures. This newly developed clinical, physical assessment of upper extremity lymphedema provides standardization and a single score that accounts for multiple constructs. Next steps include evaluation of sensitivity to change, which would establish usefulness to evaluate intervention efficacy.
Assuntos
Linfedema Relacionado a Câncer de Mama/fisiopatologia , Avaliação da Deficiência , Inquéritos e Questionários/normas , Extremidade Superior/fisiopatologia , Atividades Cotidianas , Pesos e Medidas Corporais , Feminino , Humanos , Variações Dependentes do Observador , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Método Simples-CegoRESUMO
PURPOSE: Financial toxicity after breast cancer may be exacerbated by adverse treatment effects, like breast cancer-related lymphedema. As the first study of long-term out-of-pocket costs for breast cancer survivors in the USA with lymphedema, this mixed methods study compares out-of-pocket costs for breast cancer survivors with and without lymphedema. METHODS: In 2015, 129 breast cancer survivors from Pennsylvania and New Jersey completed surveys on demographics, economically burdensome events since cancer diagnosis, cancer treatment factors, insurance, and comorbidities; and prospective monthly out-of-pocket cost diaries over 12 months. Forty participants completed in-person semi-structured interviews. GLM regression predicted annual dollar amount estimates. RESULTS: 46.5% of participants had lymphedema. Mean age was 63 years (SD = 8). Average time since cancer diagnosis was 12 years (SD = 5). Over 98% had insurance. Annual adjusted health-related out-of-pocket costs excluding productivity losses totaled $2306 compared to $1090 (p = 0.006) for those without lymphedema, or including productivity losses, $3325 compared to $2792 (p = 0.55). Interviews suggested that the cascading nature of economic burden on long-term savings and work opportunities, and insufficiency of insurance to cover lymphedema-related needs drove cost differences. Higher costs delayed retirement, reduced employment, and increased inability to access lymphedema care. CONCLUSIONS: Long-term cancer survivors with lymphedema may face up to 112% higher out-of-pocket costs than those without lymphedema, which influences lymphedema management, and has lasting impact on savings and productivity. Findings reinforce the need for actions at policy, provider, and individual patient levels, to reduce lymphedema costs. Future work should explore patient-driven recommendations to reduce economic burden after cancer.
Assuntos
Neoplasias da Mama/economia , Sobreviventes de Câncer/estatística & dados numéricos , Efeitos Psicossociais da Doença , Linfedema/economia , Adulto , Idoso , Neoplasias da Mama/terapia , Sobreviventes de Câncer/psicologia , Emprego/estatística & dados numéricos , Feminino , Gastos em Saúde/estatística & dados numéricos , Humanos , Renda/estatística & dados numéricos , Seguro Saúde , Masculino , Pessoa de Meia-Idade , New Jersey , Pennsylvania , Estudos Prospectivos , Fatores Socioeconômicos , Inquéritos e QuestionáriosRESUMO
The recent pace, extent, and impact of paradigm-changing cancer prevention science has been remarkable. The American Association for Cancer Research (AACR) convened a 3-day summit, aligned with five research priorities: (i) Precancer Atlas (PCA). (ii) Cancer interception. (iii) Obesity-cancer linkage, a global epidemic of chronic low-grade inflammation. (iv) Implementation science. (v) Cancer disparities. Aligned with these priorities, AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, facilitating new global collaborative efforts in cancer control. The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1ß, PD-1, RANK-L) to cancer interception. Microbiota-driven IL-17 can induce stemness and transformation in pancreatic precursors (identifying another repurposing opportunity). Notable progress also includes hosting an obesity special conference (connecting epidemiologic and molecular perspectives to inform cancer research and prevention strategies), co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research, including targeted counter attacks on e-cigarette ad exploitation of children, Hispanics and Blacks. Following this summit, two unprecedented funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot (e.g., PCA and disparities); and the AACR-Stand Up To Cancer bold "Cancer Interception" initiative.
Assuntos
Pesquisa Biomédica/tendências , Neoplasias/prevenção & controle , Obesidade/epidemiologia , Prevenção Primária/organização & administração , Pesquisa Biomédica/organização & administração , Congressos como Assunto , Implementação de Plano de Saúde , Disparidades nos Níveis de Saúde , Humanos , Neoplasias/etnologia , Neoplasias/etiologia , Obesidade/complicações , Prevenção Primária/métodos , Prevenção Primária/tendências , Saúde Pública/estatística & dados numéricos , Saúde Pública/tendências , Sociedades Médicas/organização & administração , Sociedades Médicas/tendências , Sociedades Científicas/organização & administração , Sociedades Científicas/tendências , Estados Unidos/epidemiologiaRESUMO
Cancers of the digestive system remain highly lethal; therefore, the care of patients with malignant diseases of the digestive tract requires the expertise of providers from multiple health disciplines. Progress has been made to advance the understanding of epidemiology and genetics, diagnostic and screening evaluation, treatment modalities, and supportive care for patients with gastrointestinal cancers. At the Multi-Disciplinary Patient Care in Gastrointestinal Oncology conference at the Hershey Country Club in Hershey, Pennsylvania on 29 September 2017, the faculty members of the Penn State Health Milton S. Hershey Medical Center presented a variety of topics that focused on this oncological specialty. In this continuing medical education-certified conference, updates on the population sciences including health disparities and resistance training were presented. Progress made in various diagnostic evaluation and screening procedures was outlined. New developments in therapeutic modalities in surgical, radiation, and medical oncology were discussed. Cancer genetic testing and counseling and the supportive roles of music and arts in health and cancer were demonstrated. In summary, this disease-focused medical conference highlighted the new frontiers in gastrointestinal oncology, and showcase the multi-disciplinary care provided at the Penn State Cancer Institute.
RESUMO
BACKGROUND: Consumer credit may reflect financial hardship that patients face due to cancer treatment, which in turn may impact ability to manage health after cancer; however, credit's relationship to economic burden and health after cancer has not been evaluated. METHODS: From May to September 2015, 123 women with a history of breast cancer residing in Pennsylvania or New Jersey completed a cross-sectional survey of demographics, socioeconomic position, comorbidities, SF-12 self-rated health, economic burden since cancer diagnosis, psychosocial stress, and self-reported (poor to excellent) credit quality. Ordinal logistic regression evaluated credit's contribution to economic burden and self-rated health. RESULTS: Mean respondent age was 64 years. Mean year from diagnosis was 11.5. Forty percent of respondents were Black or Other and 60% were White. Twenty-four percent self-reported poor credit, and 76% reported good to excellent credit quality. In adjusted models, changing income, using savings, borrowing money, and being unable to purchase a health need since cancer were associated with poorer credit. Better credit was associated with 7.72 ([1.22, 14.20], p = 0.02) higher physical health t-score, and a - 2.00 ([- 3.92, - 0.09], p = 0.04) point change in psychosocial stress. CONCLUSIONS: This exploratory analysis establishes the premise for consumer credit as a marker of economic burden and health for breast cancer survivors. Future work should validate these findings in larger samples and for other health conditions. IMPLICATIONS FOR CANCER SURVIVORS: Stabilizing and monitoring consumer credit may be a potential intervention point for mitigating economic burden after breast cancer.
Assuntos
Neoplasias da Mama/economia , Sobreviventes de Câncer , Efeitos Psicossociais da Doença , Crédito e Cobrança de Pacientes , Adulto , Idoso , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/reabilitação , Sobreviventes de Câncer/estatística & dados numéricos , Custos e Análise de Custo/métodos , Estudos Transversais , Feminino , Gastos em Saúde/estatística & dados numéricos , Humanos , Renda , Modelos Logísticos , Pessoa de Meia-Idade , Crédito e Cobrança de Pacientes/normas , Crédito e Cobrança de Pacientes/estatística & dados numéricos , Autorrelato , Estados Unidos/epidemiologiaRESUMO
INTRODUCTION: Breast cancer survivors face dual challenges: long term sequelae of treatment, and risk of recurrent disease. Obesity and a sedentary lifestyle complicate both challenges. The WISER Survivor trial assessed the effects of exercise and/or weight-loss on lymphedema, biomarkers of breast cancer recurrence, and quality of life. We report on the innovative transdisciplinary design of this trial and report attrition rates. METHODS: This one year trial randomized breast cancer survivors who had a BMI of ≥25kg/m2, were sedentary and had breast-cancer-related-lymphedema to 1) exercise (weight training and aerobic exercise) 2) weight-loss 3) exercise and weight-loss 4) or control group. Innovative aspects included: adaptation of a community-based weight training program to a largely home-based program; use of a commercial meal replacement system as part of the lifestyle modification weight-loss program; inclusion of measures of cost-effectiveness to enable economic evaluations; and alignment with a parallel mouse model for breast cancer recurrence to enable transdisciplinary research. In this model, mice bearing dormant residual tumor cells, which spontaneously relapse, were placed on a high-fat diet. Overweight animals were randomly assigned to exercise, calorie restriction, both, or control group and followed for cancer recurrence. The animal model will guide mechanistic biomarkers to be tested in the human trial. RESULTS & DISCUSSION: 351 participants were randomized; 13 experienced breast cancer recurrence during the trial. Of the 338 participants without recurrence, 83% completed the trial. The WISER Survivor trial will show the effects of exercise and weight-loss on lymphedema outcomes, biomarkers of recurrence and quality of life. NCT ClinicalTrials.gov registration #: NCT01515124.
Assuntos
Neoplasias da Mama/terapia , Sobreviventes de Câncer , Exercício Físico , Linfedema/terapia , Obesidade/terapia , Programas de Redução de Peso/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores Tumorais , Neoplasias da Mama/complicações , Neoplasias da Mama/epidemiologia , Análise Custo-Benefício , Dieta Redutora/métodos , Feminino , Humanos , Estilo de Vida , Linfedema/epidemiologia , Linfedema/etiologia , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Obesidade/epidemiologia , Qualidade de Vida , Projetos de Pesquisa , Treinamento Resistido/métodos , Programas de Redução de Peso/economiaRESUMO
Introduction. High BMI is a risk factor for upper body breast cancer-related lymphedema (BCRL) onset. Black cancer survivors are more likely to have high BMI than White cancer survivors. While observational analyses suggest up to 2.2 times increased risk of BCRL onset for Black breast cancer survivors, no studies have explored race or other social factors that may affect BCRL severity, operationalized by interlimb volume difference (ILD). Materials and Methods. ILD was measured by perometry for 296 overweight (25 > BMI < 50) Black (n = 102) or White (n = 194) breast cancer survivors (>6 months from treatment) in the WISER Survivor trial. Multivariable linear regression examined associations between social and physical factors and ILD. Results. Neither Black race (-0.26, p = 0.89) nor BMI (0.22, p = 0.10) was associated with ILD. Attending college (-4.89, p = 0.03) was the strongest factor associated with ILD, followed by having more lymph nodes removed (4.75, p = 0.01), >25% BCRL care adherence (4.10, p = 0.01), and years since treatment (0.55, p < 0.001). Discussion. Neither race nor BMI was associated with ILD among overweight cancer survivors. Education, a proxy for resource level, was the strongest factor associated with greater ILD. Tailoring physical activity and weight loss interventions designed to address BCRL severity by resource rather than race should be considered.
Assuntos
Neoplasias da Mama , Linfedema/prevenção & controle , Obesidade/prevenção & controle , Braço , Índice de Massa Corporal , Etnicidade , Feminino , Humanos , Linfedema/etnologia , Masculino , Pessoa de Meia-Idade , Obesidade/etnologia , Fatores de Risco , Fatores Socioeconômicos , SobreviventesRESUMO
BACKGROUND: Given evidence shows physical activity, a healthful diet and weight management can improve cancer outcomes and reduce chronic disease risk, the major cancer organisations and health authorities have endorsed related guidelines for cancer survivors. Despite these, and a growing evidence base on effective lifestyle interventions, there is limited uptake into survivorship care. METHODS/DESIGN: Healthy Living after Cancer (HLaC) is a national dissemination and implementation study that will evaluate the integration of an evidence-based lifestyle intervention for cancer survivors into an existing telephone cancer information and support service delivered by Australian state-based Cancer Councils. Eligible participants (adults having completed cancer treatment with curative intent) will receive 12 health coaching calls over 6 months from Cancer Council nurses/allied health professionals targeting national guidelines for physical activity, healthy eating and weight control. Using the RE-AIM evaluation framework, primary outcomes are service-level indicators of program reach, adoption, implementation/costs and maintenance, with secondary (effectiveness) outcomes of patient-reported anthropometric, behavioural and psychosocial variables collected at pre- and post-program completion. The total participant accrual target across four participating Cancer Councils is 900 over 3 years. DISCUSSION: The national scope of the project and broad inclusion of cancer survivors, alongside evaluation of service-level indicators, associated costs and patient-reported outcomes, will provide the necessary practice-based evidence needed to inform future allocation of resources to support healthy living among cancer survivors. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ANZCTR)--ACTRN12615000882527 (registered on 24/08/2015).
Assuntos
Promoção da Saúde/métodos , Estilo de Vida , Neoplasias/reabilitação , Adulto , Idoso , Austrália , Análise Custo-Benefício , Dieta , Exercício Físico , Feminino , Promoção da Saúde/economia , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/psicologia , Projetos de Pesquisa , Apoio Social , Inquéritos e Questionários , Sobreviventes , Telefone , Adulto JovemRESUMO
PURPOSE: The purpose of this work was to evaluate the patient-borne financial cost of common, adverse breast cancer treatment-associated effects, comparing cost across women with or without these side effects. METHODS: Two hundred eighty-seven Australian women diagnosed with early-stage breast cancer were prospectively followed starting at 6 months post-surgery for 12 months, with three monthly assessments of detailed treatment-related side effects and their direct and indirect patient costs attributable to breast cancer. Bootstrapping statistics were used to analyze cost data, and adjusted logistic regression was used to evaluate the association between costs and adverse events from breast cancer. Costs were inflated and converted from 2002 Australian to 2014 US dollars. RESULTS: More than 90 % of women experienced at least one adverse effect (i.e., post-surgical issue, reaction to radiotherapy, upper-body symptoms or reduced function, lymphedema, fatigue, or weight gain). On average, women paid $5,636 (95 % confidence interval (CI), $4,694, $6,577) in total costs. Women with any one of the following symptoms (fatigue, reduced upper-body function, upper-body symptoms) or women who report ≥4 adverse treatment-related effects, have 1.5 to nearly 4 times the odds of having higher healthcare costs than women who do not report these complaints (p < 0.05). CONCLUSIONS: Women face substantial economic burden due to a range of treatment-related health problems, which may persist beyond the treatment period. Improving breast cancer care by incorporating prospective surveillance of treatment-related side effects and strategies for prevention and treatment of concerns (e.g., exercise) has real potential for reducing patient-borne costs.
Assuntos
Antineoplásicos/efeitos adversos , Antineoplásicos/economia , Neoplasias da Mama/terapia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Adulto , Idoso , Antineoplásicos/uso terapêutico , Austrália , Neoplasias da Mama/economia , Exercício Físico , Fadiga/epidemiologia , Feminino , Humanos , Modelos Logísticos , Linfedema/epidemiologia , Pessoa de Meia-Idade , Estudos Prospectivos , Padrão de Cuidado , Inquéritos e Questionários , Aumento de PesoRESUMO
Obesity is a risk factor for breast cancer recurrence and death. Women who reside in rural areas have higher obesity prevalence and suffer from breast cancer treatment-related disparities compared to urban women. The objective of this 5-year randomized controlled trial is to compare methods for delivering extended care for weight loss maintenance among rural breast cancer survivors. Group phone-based counseling via conference calls addresses access barriers, is more cost-effective than individual phone counseling, and provides group support which may be ideal for rural breast cancer survivors who are more likely to have unmet support needs. Women (n=210) diagnosed with Stage 0 to III breast cancer in the past 10 years who are ≥ 3 months out from initial cancer treatments, have a BMI 27-45 kg/m(2), and have physician clearance were enrolled from multiple cancer centers. During Phase I (months 0 to 6), all women receive a behavioral weight loss intervention delivered through group phone sessions. Women who successfully lose 5% of weight enter Phase II (months 6 to 18) and are randomized to one of two extended care arms: continued group phone-based treatment or a mail-based newsletter. During Phase III, no contact is made (months 18 to 24). The primary outcome is weight loss maintenance from 6 to 18 months. Secondary outcomes include quality of life, serum biomarkers, and cost-effectiveness. This study will provide essential information on how to reach rural survivors in future efforts to establish weight loss support for breast cancer survivors as a standard of care.
Assuntos
Neoplasias da Mama/epidemiologia , Aconselhamento/métodos , Obesidade/epidemiologia , Obesidade/terapia , População Rural , Redução de Peso , Idoso , Índice de Massa Corporal , Pesos e Medidas Corporais , Análise Custo-Benefício , Aconselhamento/economia , Dieta , Exercício Físico , Feminino , Humanos , Relações Interpessoais , Pessoa de Meia-Idade , Obesidade/psicologia , Seleção de Pacientes , Qualidade de Vida , Projetos de Pesquisa , Grupos de Autoajuda , Fatores Socioeconômicos , Sobreviventes , TelefoneRESUMO
BACKGROUND: The primary aims of this hybrid Type 1 effectiveness-implementation trial were to quantitatively assess whether an evidence-based exercise intervention for breast cancer survivors, Strength After Breast Cancer, was safe and effective in a new setting and to qualitatively assess barriers to implementation. METHODS: A cohort of 84 survivors completed measurements related to limb volume, muscle strength, and body image at baseline, 67 survivors completed measurements 12 months later. Qualitative methods were used to understand barriers to implementation experienced by referring oncology clinicians and physical therapists who delivered the program. RESULTS: Similar to the efficacy trial, the revised intervention demonstrated safety with regard to lymphedema, and led to improvements in lymphedema symptoms, muscular strength, and body image. Comparison of effects in the effectiveness trial to effects in the efficacy trial revealed larger strength increases in the efficacy trial than in the effectiveness trial (P < .04), but few other differences were found. Qualitative implementation data suggested significant barriers around intervention characteristics, payment, eligibility criteria, the referral process, the need for champions (ie, advocates), and the need to adapt during implementation of the intervention, which should be considered in future dissemination and implementation efforts. CONCLUSIONS: This trial successfully demonstrated that a physical therapy led strength training program for breast cancer survivors can be implemented in a community setting while retaining the effectiveness and safety of the clinical trial. However, during the translation process, strategies to reduce barriers to implementation are required. This new program can inform larger scale dissemination and implementation efforts.
Assuntos
Atitude do Pessoal de Saúde , Neoplasias da Mama/reabilitação , Medicina Integrativa/organização & administração , Linfedema/terapia , Treinamento Resistido , Sobreviventes/psicologia , Adulto , Idoso , Imagem Corporal , Neoplasias da Mama/fisiopatologia , Neoplasias da Mama/psicologia , Medicina Baseada em Evidências , Exercício Físico/fisiologia , Exercício Físico/psicologia , Feminino , Humanos , Medicina Integrativa/economia , Pessoa de Meia-Idade , Força Muscular , Músculo Esquelético/fisiologia , Seleção de Pacientes , Desenvolvimento de Programas , Avaliação de Programas e Projetos de Saúde , Encaminhamento e Consulta , Treinamento Resistido/efeitos adversos , Treinamento Resistido/economia , Treinamento Resistido/organização & administraçãoRESUMO
The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.
Assuntos
Neoplasias da Mama/cirurgia , Prestação Integrada de Cuidados de Saúde/organização & administração , Linfedema/epidemiologia , Dor/epidemiologia , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/prevenção & controle , Qualidade de Vida , Adulto , Idoso , American Cancer Society , Neoplasias da Mama/mortalidade , Neoplasias da Mama/reabilitação , Congressos como Assunto , Avaliação da Deficiência , Feminino , Seguimentos , Humanos , Incidência , Estudos Longitudinais , Linfedema/etiologia , Linfedema/reabilitação , Mastectomia/efeitos adversos , Mastectomia/métodos , Mastectomia/reabilitação , Pessoa de Meia-Idade , Modelos Organizacionais , Debilidade Muscular/epidemiologia , Debilidade Muscular/etiologia , Debilidade Muscular/reabilitação , Dor/etiologia , Dor/reabilitação , Prevenção Primária/métodos , Estudos Prospectivos , Amplitude de Movimento Articular/fisiologia , Índice de Gravidade de Doença , Fatores de Tempo , Extremidade Superior/fisiopatologiaRESUMO
BACKGROUND: The purpose of this study was to determine 1) the test-retest reliability of adult accelerometer-measured physical activity, and 2) how data processing decisions affect physical activity levels and test-retest reliability. METHODS: 143 people wore the ActiGraph accelerometer for 2 7-day periods, 1 to 4 weeks apart. Five algorithms, varying nonwear criteria (20 vs. 60 min of 0 counts) and minimum wear requirements (6 vs. 10 hrs/day for ≥ 4 days) and a separate algorithm requiring ≥ 3 counts per min and ≥ 2 hours per day, were used to process the accelerometer data. RESULTS: Processing the accelerometer data with different algorithms resulted in different levels of counts per day, sedentary, and moderate-to-vigorous physical activity. Reliability correlations were very good to excellent (ICC = 0.70-0.90) for almost all algorithms and there were no significant differences between physical activity measures at Time 1 and Time 2. CONCLUSIONS: This paper presents the first assessment of test-retest reliability of the Actigraph over separate administrations in free-living subjects. The ActiGraph was highly reliable in measuring activity over a 7-day period in natural settings but data were sensitive to the algorithms used to process them.
Assuntos
Algoritmos , Coleta de Dados/instrumentação , Coleta de Dados/métodos , Exercício Físico , Adulto , Índice de Massa Corporal , Processamento Eletrônico de Dados , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Minnesota , Reprodutibilidade dos Testes , Características de Residência , Fatores SocioeconômicosRESUMO
BACKGROUND: The factors influencing exercise adherence are not well characterized in women in their premenopausal years. METHODS: The purpose of this report is to provide an analysis of demographic factors contributing to women's adherence to a 2-year twice-weekly weight training intervention. Overweight and obese premenopausal women were randomized to a control or intervention group. RESULTS: During the supervised period of the intervention (months 1 to 4), adherence was significantly lower among those with a higher level of education and among unmarried women with children aged 6 to 12 compared with married women without children (F = 4.83, P = .004). Overall adherence during the supervised and unsupervised periods was 95.4% and 64.5%, respectively (unadjusted mean). During year 1, white women were significantly more adherent to the intervention (70.3%) than women of color (48.6%). Non-married women with children 13 years or older were significantly less adherent than married women with children 5 years or younger (36.3% versus 75.4%, respectively, P < .007). Overall adherence was 51.4% in year 2. CONCLUSIONS: Interventions and public health recommendations need to further consider how to engage communities to provide effective support for long-term adherence to fitness center based exercise of all women, regardless of demographics.
Assuntos
Participação da Comunidade/estatística & dados numéricos , Academias de Ginástica/estatística & dados numéricos , Comportamentos Relacionados com a Saúde , Promoção da Saúde/métodos , Treinamento Resistido/estatística & dados numéricos , Adulto , Composição Corporal , Índice de Massa Corporal , Participação da Comunidade/tendências , Características da Família , Relações Familiares , Feminino , Humanos , Pessoa de Meia-Idade , Minnesota , Comportamento Sedentário , Apoio Social , Fatores Socioeconômicos , Fatores de TempoRESUMO
The authors examined the feasibility, acceptability, and potential for physical activity behavior change of a 21-week, 10,000 Steps program in an academic work site. In a pre-post, noncontrolled study design, participants were supplied a pedometer, online resource, and health promotional activities. Means, medians, ranges, and frequencies of self-reported average daily steps (ADS) described physical activity behavior change. An online exit survey assessed the acceptability of the intervention. Of 1,322 eligible participants, 619 (47%) registered; 74% of participants tracked step counts at least once, and 57 (9%) tracked them all 21 weeks. The proportion of cohort participants with < 7,499 ADS tracking all 21 weeks was significantly less than that same cohort tracking only at baseline (p < .02). Survey results showed that 85% of the participants reported general satisfaction with content and navigation of the program Web site. Results suggest elements of feasibility and acceptability but limited potential for physical activity behavior change. Future studies should assess pre-enrollment ADS and barriers to retaining participants.